Zhengye Biotechnology Holding Limited (ZYBT)
NasdaqCM
Price as at 1 Oct 2026, 04:12 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Zhengye Biotechnology Holding Limited trades at $1.20. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its ZYBT data?
Fundamentals for ZYBT come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 04:12 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ZYBT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.